Eagle Asset Management Inc Coherus Bio Sciences, Inc. Transaction History

Eagle Asset Management Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 09, 2023	BUY	$3.79 - $8.3 $49,758 - $108,970	13,129 New	13,129 $56,000
Q2 2022 Aug 10, 2022	SELL	$5.86 - $13.23 $1.43 Million - $3.22 Million	-243,404 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$10.92 - $16.41 $1.33 Million - $2 Million	-121,931 Reduced 33.38%	243,404 $3.14 Million
Q4 2021 Feb 11, 2022	SELL	$15.81 - $18.99 $1.06 Million - $1.28 Million	-67,289 Reduced 15.55%	365,335 $6.12 Million
Q3 2021 Nov 10, 2021	SELL	$12.68 - $17.79 $810,467 - $1.14 Million	-63,917 Reduced 12.87%	432,624 $6.95 Million
Q2 2021 Aug 11, 2021	BUY	$12.95 - $15.41 $1.48 Million - $1.76 Million	114,033 Added 29.81%	496,541 $6.87 Million
Q1 2021 May 14, 2021	SELL	$14.42 - $21.39 $204,937 - $303,994	-14,212 Reduced 3.58%	382,508 $5.57 Million
Q4 2020 Feb 12, 2021	SELL	$16.56 - $18.94 $127,694 - $146,046	-7,711 Reduced 1.91%	396,720 $6.89 Million
Q3 2020 Nov 12, 2020	BUY	$17.41 - $19.89 $115,445 - $131,890	6,631 Added 1.67%	404,431 $7.61 Million
Q2 2020 Aug 12, 2020	BUY	$14.43 - $19.16 $5.74 Million - $7.62 Million	397,800 New	397,800 $6.89 Million

130

67.8M

1.68M

91.8K

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $71.5M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

Get notified when there are updates to the investment portfolio of Eagle Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Eagle Asset Management Inc with notifications on news.